{"nctId":"NCT00970632","briefTitle":"A Study of Tadalafil in Men With Benign Prostatic Hyperplasia","startDateStruct":{"date":"2009-10"},"conditions":["Benign Prostatic Hyperplasia (BPH)"],"count":511,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo tablet","Drug: Placebo capsule"]},{"label":"Tadalafil 5 milligram (mg)","type":"EXPERIMENTAL","interventionNames":["Drug: Tadalafil 5 mg"]},{"label":"Tamsulosin 0.4 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Tamsulosin"]}],"interventions":[{"name":"Tadalafil 5 mg","otherNames":["Cialis","LY450190"]},{"name":"Placebo tablet","otherNames":[]},{"name":"Tamsulosin","otherNames":[]},{"name":"Placebo capsule","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men 45 years of age or older with benign prostatic hyperplasia (BPH) also referred to as BPH-lower urinary tract symptoms (LUTS) on the disease diagnostic criteria at the start of study.\n* Provide signed informed consent at the start of the study.\n* Agree not to use any other approved or experimental pharmacologic BPH, overactive bladder (OAB), or erectile dysfunction (ED) treatments anytime during the study.\n* Have not taken finasteride therapy for at least 3 months before study drug is dispensed and dutasteride therapy for at least 6 months before study drug is dispensed.\n* Have not taken other BPH therapy (including herbal preparations), OAB therapy, ED therapy for at least 4 weeks prior to study drug is dispensed.\n* Have LUTS with a total International Prostate Symptom Score (IPSS) greater than or equal to 13 when study drug is dispensed.\n* Have reduced urine flow (measured by special toilet equipment).\n* Demonstrate compliance with study drug administration requirements.\n\nExclusion Criteria:\n\n* Treated with nitrates\n* Have unstable angina or angina that requires treatment.\n* Have had any of the following in the past 90 days: Heart attack, also known as a myocardial infarction (MI); Heart bypass surgery (called coronary artery bypass graft surgery); Had a procedure to open up blood vessels in the heart known as angioplasty or stent placement (percutaneous coronary intervention).\n* Have very high or very low blood pressure.\n* Have certain neurological conditions associated with bladder problems or injuries to brain or spinal cord within a specified time of starting this study.\n* Have uncontrolled diabetes.\n* Have prostate cancer, are being treated for cancer.\n* Have prostate specific antigen (PSA) greater than 10 nanograms per milliliter (ng/mL) at the start of study.","healthyVolunteers":false,"sex":"MALE","minimumAge":"45 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Total International Prostate Symptom Score (IPSS) at 12 Weeks","description":"The IPSS Total Score was obtained by combining the scores of the responses to Component Questions 1-7. Each question was scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represented greater severity of symptoms. Least Squares (LS) Mean of change from baseline to endpoint (Week 12 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.2","spread":"0.5"},{"groupId":"OG001","value":"-6.3","spread":"0.5"},{"groupId":"OG002","value":"-5.7","spread":"0.5"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total International Prostate Symptom Score (IPSS) at 4 Weeks","description":"The IPSS Total Score was obtained by combining the scores of the responses to Component Questions 1-7. Each question was scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represented greater severity of symptoms. Least Squares (LS) Mean of change from baseline to endpoint (Week 4 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.3","spread":"0.4"},{"groupId":"OG001","value":"-5.5","spread":"0.4"},{"groupId":"OG002","value":"-5.7","spread":"0.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore at 12 Weeks","description":"IPSS storage (irritative) subscore was the sum of Component Questions 2, 4 and 7 of the IPSS questionnaire. Scores ranged from 0 (no irritative symptoms) to 5 (frequent irritative symptoms); therefore, the 3 questions of the irritative subscore ranged from 0 to 15. Least Squares (LS) Mean of change from baseline to endpoint (Week 12 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"0.2"},{"groupId":"OG001","value":"-2.2","spread":"0.2"},{"groupId":"OG002","value":"-2.2","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore at 12 Weeks.","description":"IPSS voiding (obstructive) subscore was the sum of Component Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores ranged from 0 (no obstructive symptoms)-5 (frequent obstructive symptoms); therefore, the 4 questions of the obstructive score ranged from 0-20. Least Squares (LS) Mean of change from baseline to endpoint (Week 12 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.6","spread":"0.3"},{"groupId":"OG001","value":"-4.1","spread":"0.3"},{"groupId":"OG002","value":"-3.5","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in International Prostate Symptom Score (IPSS) Nocturia Question at 12 Weeks","description":"The IPSS nocturia question (Component Question 7) measured nocturia (need to urinate at night) over the past 4 weeks. Scores ranged from 0 (no episodes of nocturia)-5 (5 or more episodes of nocturia). Least Squares (LS) Mean of change from baseline to endpoint (Week 12 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.1"},{"groupId":"OG001","value":"-0.5","spread":"0.1"},{"groupId":"OG002","value":"-0.5","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in International Prostate Symptom Score (IPSS) Quality of Life (QoL) Index at 12 Weeks","description":"IPSS QoL assessed QoL by urinary symptoms, with scores ranging from 0 (delighted)-6 (terrible). Least Squares (LS) Mean of change from baseline to endpoint (Week 12 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"0.1"},{"groupId":"OG001","value":"-1.3","spread":"0.1"},{"groupId":"OG002","value":"-1.1","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Modified International Prostate Symptom Score (mIPSS) at 1 Week","description":"The mIPSS Total Score covered a time period of 1 week and was obtained by combining scores of responses to Component Questions 1-7. Each question was scored from 0-5 for an mIPSS range of 0-35 points; higher numerical scores represented greater severity of symptoms. Least Squares (LS) Mean of change from baseline to endpoint (Week 1 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"0.4"},{"groupId":"OG001","value":"-4.0","spread":"0.4"},{"groupId":"OG002","value":"-4.0","spread":"0.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Benign Prostatic Hyperplasia Impact Index (BII) at 4 Weeks","description":"BII was a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores ranged from 0-13; higher scores represented increased perceived impact of BPH-lower urinary tract symptoms (LUTS) on overall health. Least Squares (LS) Mean of change from baseline to endpoint (Week 4 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.2"},{"groupId":"OG001","value":"-1.2","spread":"0.2"},{"groupId":"OG002","value":"-1.3","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Benign Prostatic Hyperplasia Impact Index (BII) at 12 Weeks","description":"BII was a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores ranged from 0-13; higher scores represented increased perceived impact of BPH-lower urinary tract symptoms (LUTS) on overall health. Least Squares (LS) Mean of change from baseline to endpoint (Week 12 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"0.2"},{"groupId":"OG001","value":"-1.7","spread":"0.2"},{"groupId":"OG002","value":"-1.5","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Patient Global Impression of Improvement (PGI-I) at 12 Weeks","description":"The PGI-I was a participant-rated instrument that measured the improvement or worsening of the participant's symptoms based on a 7-point scale at Week 12. A score of 1=participant felt symptoms were \"very much better\"; score of 2=participant felt symptoms were \"much better\"; score of 3=participant felt symptoms were \"a little better\"; score of 4=participant felt \"no change\" in symptoms; score of 5=participant felt symptoms were \"a little worse\"; score of 6=participant felt symptoms were \"much worse\"; score of 7=participant felt symptoms were \"very much worse\".","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"28","spread":null},{"groupId":"OG002","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"52","spread":null},{"groupId":"OG002","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"56","spread":null},{"groupId":"OG002","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinician Global Impression of Improvement (CGI-I) at 12 Weeks","description":"The CGI-I was an investigator-rated instrument that measured improvement or worsening of the participant's symptoms based on a 7-point scale. A score of 1=participant felt symptoms were \"very much better\"; score of 2=participant felt symptoms were \"much better\"; score of 3=participant felt symptoms were \"a little better\"; score of 4=participant felt \"no change\" in symptoms; score of 5=participant felt symptoms were \"a little worse\"; score of 6=participant felt symptoms were \"much worse\"; score of 7=participant felt symptoms were \"very much worse\".","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"58","spread":null},{"groupId":"OG002","value":"65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"50","spread":null},{"groupId":"OG002","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Satisfaction Scale - Benign Prostatic Hyperplasia (TSS-BPH) at 12 Weeks: Overall","description":"The TSS-BPH was a validated participant-rated instrument that measured participant satisfaction with treatment based on a 13-item questionnaire. The overall TSS-BPH score was converted to a percentage of the maximum value possible (percent ranged from 0-100) with lower scores indicating greater satisfaction.","paramType":"MEDIAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.9","spread":"17.50"},{"groupId":"OG001","value":"22.2","spread":"17.74"},{"groupId":"OG002","value":"28.9","spread":"16.49"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in International Index of Erectile Function (IIEF) Erectile Function (EF) Domain at 12 Weeks","description":"IIEF measured self-reported EF over the past 4 weeks. Scores ranged from 0 (low or no EF)-5 (high EF) on 6 questions (1-5, 15 of the IIEF). Total EF Domain scores ranged from 1-30. Least Squares (LS) Mean of change from baseline to endpoint (Week 12 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"0.8"},{"groupId":"OG001","value":"6.0","spread":"0.8"},{"groupId":"OG002","value":"1.7","spread":"0.8"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Peak Urine Flow Rate (Q-Max) at 12 Weeks","description":"Q-max (peak urine flow rate) was measured in milliliters per second (mL/sec) using a standard calibrated flowmeter. At each visit, a uroflowmetry assessment was considered valid and data were included in the analyses only if the prevoid total bladder volume (assessed by ultrasound) was ≥150 to ≤550 mL and the voided volume (V-comp) was ≥125 mL.","paramType":"MEDIAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"4.84"},{"groupId":"OG001","value":"1.6","spread":"5.49"},{"groupId":"OG002","value":"1.6","spread":"4.06"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean Urine Flow Rate (Q-Mean) at 12 Weeks","description":"Q-mean (mean urine flow rate) was measured in milliliters per second (mL/sec) using a standard calibrated flowmeter. At each visit, a uroflowmetry assessment was considered valid and data were included in the analyses only if the prevoid total bladder volume (assessed by ultrasound) was ≥150 to ≤550 mL and the voided volume (V-comp) was \\>=125 mL.","paramType":"MEDIAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":"2.72"},{"groupId":"OG001","value":"1.25","spread":"3.24"},{"groupId":"OG002","value":"0.70","spread":"3.03"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Volume of Voided Urine (V-Comp) at 12 Weeks","description":"V-comp (volume of urine voided) was measured in milliliters (mL) using a standard calibrated flowmeter. At each visit, a uroflowmetry assessment was considered valid and data were included in the analyses only if the prevoid total bladder volume (assessed by ultrasound) was ≥150 to ≤550 mL and V-comp was ≥125 mL.","paramType":"MEDIAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"110.92"},{"groupId":"OG001","value":"11.0","spread":"101.45"},{"groupId":"OG002","value":"16.0","spread":"109.30"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Postvoid Residual Volume (PVR) at 12 Weeks","description":"PVR was the amount of urine remaining in the bladder after void completion.","paramType":"MEDIAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"56.48"},{"groupId":"OG001","value":"-1.0","spread":"46.97"},{"groupId":"OG002","value":"-5.5","spread":"59.21"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":171},"commonTop":["Nasopharyngitis","Headache","Dizziness","Back pain","Dyspepsia"]}}}